PRIMARY AND SECONDARY CARNITINE DEFICIENCY SYNDROMES

被引:107
作者
PONS, R
DEVIVO, DC
机构
[1] COLUMBIA PRESBYTERIAN MED CTR,DEPT NEUROL,COLLEEN GIBLIN LABS PEDIAT NEUROL RES,NEW YORK,NY 10032
[2] COLUMBIA PRESBYTERIAN MED CTR,DEPT PEDIAT,COLLEEN GIBLIN LABS PEDIAT NEUROL RES,NEW YORK,NY 10032
关键词
D O I
10.1177/0883073895010002S03
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The objective of this article is to review primary and secondary causes of carnitine deficiency, emphasizing recent advances in our knowledge of fatty acid oxidation. It is now understood that the cellular metabolism of fatty acids requires the cytosolic carnitine cycle and the mitochondrial beta-oxidation cycle. Carnitine is central to the translocation of the long chain acyl-CoAs across the inner mitochondrial membrane. The mitochondrial beta-oxidation cycle is composed of a newly described membrane-bound system and the classic matrix compartment system. Very long chain acyl-CoA dehydrogenase and the trifunctional enzyme complex are embedded in the inner mitochondrial membrane, and metabolize the long chain acyl-CoAs. The chain shortened acyl-CoAs are further degraded by the well-known system in the mitochondrial matrix. Numerous metabolic errors have been described in the two cycles of fatty acid oxidation; all are transmitted as autosomal recessive traits. Primary or secondary carnitine deficiency is present in all these clinical conditions except carnitine palmitoyltransferase type I and the classic adult form of camitine palmitoyltransferase type II deficiency. The sole example of primary camitine deficiency is the genetic defect involving the active transport across the plasmalemmal membrane. This condition responds dramatically to oral carnitine therapy. The secondary carnitine deficiencies respond less obviously to carnitine replacement. These conditions are managed by high carbohydrate, low fat frequent feedings, and vitamin/cofactor supplementation (eg, camitine, glycine, and riboflavin). Medium chain triglycerides may be useful in the dietary management of patients with inborn errors of the cytosolic carnitine cycle or the mitochondrial membrane-bound long chain specific beta-oxidation system.
引用
收藏
页码:S2 / &
相关论文
共 148 条
  • [51] GELLERA C, 1992, AM J HUM GENET, V51, P168
  • [52] HYPOGLYCEMIA, HEPATIC-DYSFUNCTION, MUSCLE WEAKNESS, CARDIOMYOPATHY, FREE CARNITINE DEFICIENCY AND LONG-CHAIN ACYLCARNITINE EXCESS RESPONSIVE TO MEDIUM CHAIN TRIGLYCERIDE DIET
    GLASGOW, AM
    ENGEL, AG
    BIER, DM
    PERRY, LW
    DICKIE, M
    TODARO, J
    BROWN, BI
    UTTER, MF
    [J]. PEDIATRIC RESEARCH, 1983, 17 (05) : 319 - 326
  • [53] HALE DE, 1989, PEDIATR RES, V25, pA199
  • [54] FATTY-ACID OXIDATION DISORDERS - A NEW CLASS OF METABOLIC DISEASES
    HALE, DE
    BENNETT, MJ
    [J]. JOURNAL OF PEDIATRICS, 1992, 121 (01) : 1 - 11
  • [55] HALLGRIMUR G, 1985, AM J PHYSIOL, V248, pG313
  • [56] HANGENFELDT L, 1990, J PEDIATR, V116, P387
  • [57] MUSCLE CARNITINE DEFICIENCY AND FATAL CARDIOMYOPATHY
    HART, ZH
    CHANG, CH
    DIMAURO, S
    FAROOKI, Q
    AYYAR, R
    [J]. NEUROLOGY, 1978, 28 (02) : 147 - 151
  • [58] HOLME E, 1989, LANCET, V2, P469
  • [59] HORIUCHI M, 1993, BIOCHIM BIOPHYS ACTA, V1226, P25
  • [60] LETHAL NEONATAL MULTIORGAN DEFICIENCY OF CARNITINE PALMITOYLTRANSFERASE-II
    HUG, G
    BOVE, KE
    SOUKUP, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (26) : 1862 - 1864